Bioinformatics Analysis of the Expression and Prognostic Value of PLAU Gene in Wilms' Tumor
View abstract on PubMed
Summary
This summary is machine-generated.Plasminogen activator urokinase (PLAU) is a key immune gene in Wilms' tumor (WT). High PLAU expression indicates better survival, while low expression is linked to poor prognosis and potential epigenetic regulation.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Autophagy and immunity are crucial in malignant tumor growth and represent therapeutic targets.
- Wilms' tumor (WT) is a pediatric kidney cancer where understanding immune gene involvement is vital.
Purpose Of The Study
- To identify immune genes related to autophagy in WT.
- To analyze the prognostic significance of these genes in WT patients.
Main Methods
- Utilized public datasets (TCGA, ImmPort, GeneCards) for WT.
- Screened differentially expressed immune genes associated with autophagy, identifying plasminogen activator urokinase (PLAU).
- Performed survival analysis, Cox regression, GO, KEGG, GSEA, and analyzed immune cell infiltration and epigenetic modifications.
Main Results
- PLAU expression is an independent prognostic indicator for overall survival (OS) in WT patients.
- PLAU is implicated in RNA transcription and epithelial cell migration.
- High PLAU expression correlates with increased antitumor immune cell infiltration; low expression is linked to DNA methylation and potential miR-342-3p co-regulation.
Conclusions
- PLAU serves as a reliable independent prognostic biomarker for WT.
- Low PLAU expression signifies a poorer prognosis in WT.
- Understanding PLAU's prognostic value and associated pathways can guide novel WT therapeutic strategies.

